galecto biotech is a newly founded company, focused on developing novel drugs for the treatment of fibrosis, inflammation and other serious human diseases. the company’s products target galectins, a group of proteins that play important roles in many disorders. galecto biotech’s high potency galectin modulators may open new treatment possibilities for many patients. the company, which is located in lund, sweden, is led by top-level scientists and biotech executives.
Company profile
Ticker
GLTO
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Galecto Inc.
SEC CIK
Corporate docs
Subsidiaries
PharmAkea, Inc. • Galecto Securities Corporation • Galecto Biotech AB • Galecto Biotech ApS ...
IRS number
371957007
GLTO stock data
Latest filings (excl ownership)
8-K
Other Events
26 Mar 24
S-8
Registration of securities for employees
8 Mar 24
10-K
2023 FY
Annual report
8 Mar 24
8-K
Other Events
21 Dec 23
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
23 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Oct 23
8-K
Galecto Announces Plans to Explore Strategic Alternatives
26 Sep 23
8-K
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
15 Aug 23
10-Q
2023 Q2
Quarterly report
31 Jul 23
Latest ownership filings
4
Hans T. Schambye
5 Jan 24
4
Garrett Winslow
5 Jan 24
4
Jonathan Freve
5 Jan 24
SC 13G
Otto Erik
3 Oct 23
144
Notice of proposed sale of securities
2 Oct 23
144
Notice of proposed sale of securities
2 Oct 23
144
Notice of proposed sale of securities
2 Oct 23
144
Notice of proposed sale of securities
2 Oct 23
SC 13D/A
ORBIMED ADVISORS LLC
18 Sep 23
SC 13D/A
ORBIMED ADVISORS LLC
5 Sep 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 23.08 mm | 23.08 mm | 23.08 mm | 23.08 mm | 23.08 mm | 23.08 mm |
Cash burn (monthly) | (no burn) | 438.17 k | 2.86 mm | 3.90 mm | 2.82 mm | 3.07 mm |
Cash used (since last report) | n/a | 2.61 mm | 17.03 mm | 23.19 mm | 16.77 mm | 18.30 mm |
Cash remaining | n/a | 20.47 mm | 6.05 mm | -115.16 k | 6.30 mm | 4.78 mm |
Runway (months of cash) | n/a | 46.7 | 2.1 | -0.0 | 2.2 | 1.6 |
Institutional ownership, Q2 2023
36.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 25 |
Opened positions | 3 |
Closed positions | 3 |
Increased positions | 8 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 24.59 bn |
Total shares | 9.95 mm |
Total puts | 2.80 k |
Total calls | 47.90 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Orbimed Advisors | 3.83 mm | $9.66 bn |
Novo Holdings A/S | 2.50 mm | $6.29 bn |
Cormorant Asset Management | 1.02 mm | $2.57 bn |
Soleus Capital Management | 1.00 mm | $2.52 bn |
BLK Blackrock | 273.48 k | $689.16 mm |
Geode Capital Management | 193.69 k | $488.10 mm |
Laurion Capital Management | 190.65 k | $480.44 mm |
Bridgeway Capital Management | 173.10 k | $436.21 mm |
Renaissance Technologies | 165.86 k | $418.00 k |
Vanguard | 145.96 k | $367.81 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Jan 24 | Garrett Winslow | RSU Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 100,000 |
3 Jan 24 | Freve Jonathan | RSU Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 100,000 |
3 Jan 24 | Hans T. Schambye | RSU Common Stock | Grant | Acquire A | No | No | 0 | 200,000 | 0.00 | 200,000 |
15 Aug 23 | Orbimed Advisors | Common Stock | Sell | Dispose S | Yes | No | 0.75 | 535,534 | 401.65 k | 1,510,375 |
15 Aug 23 | Orbimed Advisors | Common Stock | Sell | Dispose S | Yes | No | 0.75 | 248,819 | 186.61 k | 631,048 |
15 Aug 23 | Orbimed Advisors | Common Stock | Sell | Dispose S | Yes | No | 0.75 | 38,327 | 28.75 k | 97,204 |
31 Jul 23 | Orbimed Advisors | Common Stock | Sell | Dispose S | Yes | No | 3 | 153,078 | 459.23 k | 2,105,909 |
31 Jul 23 | Orbimed Advisors | Common Stock | Sell | Dispose S | Yes | No | 3 | 29,700 | 89.10 k | 879,867 |
31 Jul 23 | Orbimed Advisors | Common Stock | Sell | Dispose S | Yes | No | 3 | 26,622 | 79.87 k | 135,531 |